Improving Colorectal Cancer Early Screening in Portugal: Identification of Gut Microbiome Biomarkers in Stool (GUTBIOME-PT)
Launched by GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE · Dec 16, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The GUTBIOME-PT trial is studying how changes in the gut microbiome, which is the community of bacteria in our intestines, can help us detect colorectal cancer (CRC) earlier and more accurately. Colorectal cancer is a serious health issue, especially in Portugal, where it is the most common cancer and can be deadly if not found early. This research aims to find specific markers in stool samples that could indicate the presence of CRC or precancerous growths, helping to improve screening methods that are currently not very effective.
To participate in this trial, individuals must be between 40 and 74 years old and live in the Lisbon Metropolitan Area. They should be willing to give written consent and provide stool samples. It’s important to note that people with certain health conditions or a personal or family history of colorectal cancer may not be eligible. Participants can expect to contribute to important research that could lead to better early detection of CRC in the future, which is crucial for improving survival rates.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability to provide written informed consent and comply with study procedures
- • Reside in the Lisbon Metropolitan Area,, Portugal
- • Age from 40 to 74 years
- Exclusion Criteria:
- • Age \< 40 years or ≥ 75 years
- • Unable to provide informed consent
- • Refusal to provide stool samples
- • Active oncological disease
- • Personal history of CRC
- • Personal history of colon adenomas removed in the last 24 months
- • First-degree family history of CRC
- • Previous diagnosis of inflammatory bowel disease (ulcerative colitis, Crohn's disease or indeterminate colitis), inflammatory bowel syndrome, persistent and infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhoea of unknown aetiology or recurrent infection by Clostridioides difficile
- • Severe cardiovascular or heart diseases with medical diagnosis
- • Severe renal failure requiring hemodialysis
- • Severe lung disease
- • Pregnancy
About Gulbenkian Institute For Molecular Medicine
The Gulbenkian Institute for Molecular Medicine (IGMM) is a prestigious research institution dedicated to advancing the understanding of human health and disease through cutting-edge molecular biology and genetics. Located in Portugal, IGMM fosters a collaborative environment that integrates basic and clinical research, aiming to translate scientific discoveries into therapeutic innovations. The institute is committed to excellence in research, education, and the development of novel approaches to address complex medical challenges, making significant contributions to the fields of biomedical science and translational medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lisbon, , Portugal
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported